Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine-samidorphan Plus Exercise for Early Weight Gain Prevention in Schizophrenia and Bipolar Disorder
NCT06740890Phase 4Recruiting
- Sponsor
- New York State Psychiatric Institute
- Start
- Jun 2025
- Primary completion
- Apr 2027
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
A Phase 4 trial of olanzapine + samidorphan in schizophrenia, schizoaffective disorder, bipolar disorder (BD), sponsored by New York State Psychiatric Institute. Started Jun 2025; status: recruiting.
02
Drugs
olanzapine + samidorphan
03
Conditions
schizophreniaschizoaffective disorderbipolar disorder (BD)
Beyond the preview
Go deeper on NCT06740890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06740890.